Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?
Wieland D MüskensSanne A A Rongen-van DartelPiet L C M van RielEddy M M AdangPublished in: The Journal of rheumatology (2020)
The average cost per patient treated with biologics decreased after the introduction of biosimilars with a persistent trend. However, the budgetary relief due to market entry of biosimilars vanished quickly due to an increase in patients treated with biologics.